文献速递消化系统肿瘤

比较瑞戈非尼不同剂量诱导方案治疗经治转移性结直肠癌患者的随机2期研究(REARRANGE试验)

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).
PubMed 文献 · Eur J Cancer · 2022-10-14

REARRANGE试验将299例经治转移性结直肠癌患者随机分为三组:A组瑞戈非尼160mg每日一次(3周用药/1周停药),B组120mg每日一次(3周用药/1周停药),C组160mg每日一次(1周用药/1周停药)。主要终点为各组G3/G4治疗相关不良事件发生率,A、B、C组分别为60%、55%、54%。结论认为替代给药方案可行且安全,间歇给药组在临床最相关不良事件上有更高的数值改善。

要点

  • A、B、C组G3/4治疗相关不良事件发生率分别为60%、55%、54%。
  • A、B、C组中位总生存期分别为7.4、8.6、7.1个月。
  • 间歇给药组在临床最相关不良事件上有更高的数值改善,尤其前两个周期。

核心结论

  • 替代瑞戈非尼给药方案在经治转移性结直肠癌患者中可行且安全。
  • 间歇给药组在临床最相关不良事件上有更高的数值改善,尤其在前两个周期。

研究设计与样本

  • 随机2期研究,纳入在末次标准化疗期间或之后3个月内进展的转移性结直肠癌患者。
  • 患者随机接受A组瑞戈非尼160mg每日一次(3周用药/1周停药)、B组120mg每日一次(3周用药/1周停药)或C组160mg每日一次(1周用药/1周停药)。
  • 共299例随机分配至A组(n=101)、B组(n=99)、C组(n=99),297例开始治疗进入安全性分析(A组n=100,B组n=98,C组n=99)。
  • 主要终点为各组G3/G4治疗相关不良事件的发生率。

主要发现

  • G3/4治疗相关不良事件发生率A组60%、B组55%、C组54%。
  • 最常见的G3/4不良事件为高血压(A组19例、B组12例、C组20例)、疲乏(A组20例、B组14例、C组15例)、低钾血症(A组11例、B组7例、C组10例)和手足皮肤反应(A组8例、B组7例、C组3例)。
  • 中位总生存期A组7.4个月(IQR 4.0-13.7)、B组8.6个月(IQR 3.8-13.4)、C组7.1个月(IQR 4.4-12.4)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. PATIENTS AND METHODS: Patients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). The primary end-point was the percentage of patients with G3/G4 treatment-related adverse events (AEs) in each arm. RESULTS: There were 299 patients randomly assigned to arm A (n = 101), arm B (n = 99), or arm C (n = 99); 297 initiated treatments (arm A n = 100, arm B n = 98, arm C n = 99: population for safety analyses). G3/4 treatment-related AEs occurred in 60%, 55%, and 54% of patients in arms A, B, and C, respectively. The most common G3/4 AEs were hypertension (19, 12, and 20 patients), fatigue (20, 14, and 15 patients), hypokalemia (11, 7, and 10 patients), and hand-foot skin reaction (8, 7, and 3 patients). Median overall survival was 7.4 (IQR 4.0-13.7) months in arm A, 8.6 (IQR 3.8-13.4) in arm B, and 7.1 (IQR 4.4-12.4) in arm C. CONCLUSIONS: The alternative regorafenib dosing schedules were feasible and safe in patients with mCRC who had been previously treated with standard therapy. There was a higher numerical improvement on the most clinically relevant AEs in the intermittent dosing arm, particularly during the relevant first two cycles. GOV IDENTIFIER: NCT02835924.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Argilés G, Mulet N, Valladares-Ayerbes M, et al. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). Eur J Cancer. 2022. PMID: 36335783. doi:10.1016/j.ejca.2022.09.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。